vs
Side-by-side financial comparison of Americas Gold & Silver Corp (USAS) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Americas Gold & Silver Corp is the larger business by last-quarter revenue ($19.1M vs $13.7M, roughly 1.4× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -82.3%, a 158.0% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-41.3M).
Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
USAS vs XLO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $13.7M |
| Net Profit | $-15.7M | $10.4M |
| Gross Margin | 34.2% | — |
| Operating Margin | — | -86.5% |
| Net Margin | -82.3% | 75.7% |
| Revenue YoY | -28.0% | — |
| Net Profit YoY | 2.8% | 179.1% |
| EPS (diluted) | — | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.7M | ||
| Q3 25 | $19.1M | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q3 24 | $26.5M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | $-15.7M | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-13.3M | ||
| Q3 24 | $-16.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | 34.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 23.6% | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | — | -472.7% | ||
| Q3 24 | — | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | -82.3% | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | — | -452.7% | ||
| Q3 24 | -60.9% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $39.1M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $50.2M | $35.3M |
| Total Assets | $234.7M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | $39.1M | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q3 24 | — | — |
| Q4 25 | — | $35.3M | ||
| Q3 25 | $50.2M | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $10.7M | ||
| Q3 24 | $53.1M | — |
| Q4 25 | — | $154.7M | ||
| Q3 25 | $234.7M | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | — | $103.7M | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-12.5M | $-2.0M |
| Free Cash FlowOCF − Capex | $-41.3M | $-2.1M |
| FCF MarginFCF / Revenue | -216.5% | -15.3% |
| Capex IntensityCapex / Revenue | 150.8% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $-12.5M | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | $2.4M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $-41.3M | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | $-11.2M | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | -216.5% | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q3 24 | -42.2% | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | 150.8% | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q3 24 | 51.2% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
